Cel-Sci (CVM) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NanoViricides (NNVC) has outperformed Cel-Sci (CVM) over the past year, losing 8.4% versus a loss of 80.6%. Over five years, NNVC leads with a -73.2% price change compared with -99.4% for CVM. Cel-Sci is the larger company by market cap ($34.3 million vs $33.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | NNVC |
|---|---|---|
| Share price | $1.95 | $1.31 |
| Market cap | $34.30M | $33.44M |
| 1-day change | -8.45% | -9.03% |
| YTD return | -62.93% | +15.93% |
| 1-year return | -80.56% | -8.39% |
| 5-year return | -99.38% | -73.16% |
| EPS (TTM) | $-1.69 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.39 | $2.23 |
| 52-week low | $0.89 | $0.85 |
| Distance from 52-week high | -81.23% | -41.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +541.03% | +358.02% |
| Average volume | 241.50K | 445.00K |
| Shares outstanding | 17.59M | 25.52M |
| Employees | — | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed CVM by 72.2 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Healthcare · Biotechnology
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Healthcare · Biotechnology · 7 employees
CVM vs NNVC FAQ
Which is bigger, Cel-Sci or NanoViricides?
Cel-Sci (CVM) is larger, with a market capitalization of $34.30M compared with $33.44M for NanoViricides (NNVC).
Which stock has performed better over the past year, CVM or NNVC?
NNVC returned -8.39% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.